Mitochondrial DNA-related dystonia

Mitochondrial DNA-related dystonia (Orphanet code 254851) is a rare neurological condition caused by mutations in mitochondrial DNA (mtDNA) that primarily manifests as dystonia — involuntary sustained muscle contractions leading to abnormal postures and repetitive movements. Because mitochondria serve as the energy-producing organelles of cells, tissues with high energy demands such as the brain, muscles, and nervous system are particularly vulnerable. Dystonia in this context may occur as an isolated feature or, more commonly, as part of a broader mitochondrial syndrome that can include additional neurological features such as basal ganglia abnormalities, optic atrophy, sensorineural hearing loss, seizures, ataxia, and cognitive impairment. Other organ systems may also be affected, including the heart, endocrine system, and skeletal muscle, reflecting the multisystemic nature of mitochondrial disorders. The dystonia associated with mitochondrial DNA mutations can vary widely in severity, distribution (focal, segmental, or generalized), and age of onset. Several specific mtDNA mutations have been linked to dystonia, including those associated with Leigh syndrome, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), and Leber hereditary optic neuropathy (LHON)-plus phenotypes. Neuroimaging often reveals characteristic bilateral basal ganglia lesions, particularly affecting the striatum. Elevated blood or cerebrospinal fluid lactate levels may support the diagnosis, which is confirmed through molecular genetic testing of mitochondrial DNA. There is currently no cure for mitochondrial DNA-related dystonia. Treatment is primarily symptomatic and supportive. Dystonia may be managed with medications such as anticholinergics, baclofen, or benzodiazepines, and in selected cases, botulinum toxin injections or deep brain stimulation may be considered. Mitochondrial cofactor supplementation (e.g., coenzyme Q10, riboflavin, L-carnitine) is sometimes used, though evidence for efficacy remains limited. A multidisciplinary approach involving neurologists, geneticists, physiotherapists, and other specialists is essential for optimal management.

Common questions about Mitochondrial DNA-related dystonia